---
title: Validating candidate endpoints for intermediate age-related macular degeneration
  trials in a multi-centre setting-lessons from the MACUSTAR study
date: '2025-02-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39910281/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250206170938&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: For the conduct of future interventional age-related macular degeneration
  (AMD) trials, the availability of clinical study endpoints is key. However, no endpoints
  have been accepted by regulators for evaluation of treatment for intermediate (i)
  AMD, i.e. the AMD stage at highest risk of developing irreversible geographic atrophy
  or macular neovascularization. The European MACUSTAR consortium has recruited more
  than 700 individuals to develop and validate structural, functional ...
disable_comments: true
---
For the conduct of future interventional age-related macular degeneration (AMD) trials, the availability of clinical study endpoints is key. However, no endpoints have been accepted by regulators for evaluation of treatment for intermediate (i) AMD, i.e. the AMD stage at highest risk of developing irreversible geographic atrophy or macular neovascularization. The European MACUSTAR consortium has recruited more than 700 individuals to develop and validate structural, functional ...